BeyondSpring Inc.
BeyondSpring Inc. (Nasdaq: BYSI) is a clinical-stage biopharmaceutical company developing therapies for patients with high unmet medical needs. Its lead candidate, plinabulin, is a small-molecule drug being studied as an anticancer agent and to prevent chemotherapy-induced neutropenia, including in combination with… From the company’s description.
In fiscal 2025, BeyondSpring Inc. reported a net loss of $14.22M. Operations used $19.77M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What BeyondSpring Inc. does
In the company’s own words
BeyondSpring Inc. (Nasdaq: BYSI) is a clinical-stage biopharmaceutical company developing therapies for patients with high unmet medical needs. Its lead candidate, plinabulin, is a small-molecule drug being studied as an anticancer agent and to prevent chemotherapy-induced neutropenia, including in combination with docetaxel for advanced non-small cell lung cancer and with immunotherapies or radiation in several cancers. Plinabulin has been administered to more than 700 cancer patients. The company also has three small-molecule immune agents in preclinical development. BeyondSpring founded and retains an equity stake in SEED Therapeutics, which uses a targeted protein degradation platform to discover and develop drug candidates, including through collaborations with Eli Lilly and Eisai; SEED’s wholly owned oncology candidate entered Phase 1 clinical studies in January 2026. BeyondSpring’s clinical programs include a global Phase 3 study enrolling 559 patients with non-small cell lung cancer, as well as investigator-led studies in other cancer indications.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- FLORHAM PARK, NJ
- Fiscal year end
- December
- CIK
- 1677940
- SIC
- 2834
Financial performance, year by year
Fiscal 2024–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns BeyondSpring Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · BeyondSpring Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do BeyondSpring Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of BeyondSpring Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in BeyondSpring Inc.'s last four quarterly filings that the numbers alone won't show?”